Please login to the form below

Not currently logged in
Email:
Password:

Toujeo

This page shows the latest Toujeo news and features for those working in and with pharma, biotech and healthcare.

Dupixent dulls pain of diabetes slump at Sanofi

Dupixent dulls pain of diabetes slump at Sanofi

Long-acting variant Toujeo provided some succour, rising 23% to 198m. The diabetes decline was not as bad as had been predicted, but Sanofi’s cardiovascular drugs also suffered in this

Latest news

More from news
Approximately 9 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Going the distance Going the distance

    Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the new basal insulin that will be crucial to moving away from Sanofi's dependence on Lantus. ... We are very much encouraging collaboration, so we are working on pairing the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics